Collective Actions and Proprietary Rights | Part 2
Part 2: The symposium focuses on cases where proprietary rights on research inputs are posing, or may imminently pose, obstacles to biopharmaceutical R&D. Many of these cases involve diseases that have limited market potential, either because the affected population is poor or because it is small. Hence the need to reduce costs related to licensing, as well as other R&D costs, is particularly acute. These concerns may especially affect genomic innovation, where the ability to "invent around" building blocks of knowledge may be limited. Sponsored by the Center for the Study of the Public Domain and the Center for Genome, Ethics, Law and Policy.
Recorded on March 04, 2005.
Conference title: Collective Actions and Proprietary Rights 2005 : Duke University. School of Law).
Appearing: Anthony So (Director, Center for a Livable Future), introducer; Alan Bennett (Associate Vice Chancellor, Office of Research (U.C. Davis)), Willard Tom (Director, Scientific Affairs (Partner, Morgan, Lewis and Bockius, LLP)), Sandra Shotwell (Managing Partner, Alta Biomedical Group, LLC), David Martin (President and CEO, M-CAM, Inc.), speakers